Medications
Enzyme replacement therapy approved for late-onset Pompe disease
(HealthDay)—Nexviazyme (avalglucosidase alfa-ngpt) was approved for the treatment of the rare inherited disorder late-onset Pompe disease in patients 1 year of age and older, the U.S. Food and Drug Administration announced ...
Aug 11, 2021
0
85
